$250B+ across 516 licensing deals in 2025. Average deal size surges 76% in 2026. Track the biggest transactions and what they mean for your BD strategy.
Zolgensma ($1.24B), Elevidys ($820M+), and CRISPR-based Casgevy are transforming rare disease. Track AAV, CRISPR, and in vivo gene therapy licensing opportunities.
The $217B orphan drug market covers only 5% of rare diseases. 7-year exclusivity, premium pricing, and BioMarin's $4.8B Amicus deal signal massive BD opportunity.
15 FDA-approved ADCs, $13.5B market, and Enhertu leading at $3.75B. Analysis of platform deals, China-origin assets, and licensing strategy for BD executives.
Ivonescimab's $5B Summit deal, HARMONi-2 data beating Keytruda, and 9+ pipeline candidates. The hottest bispecific antibody space in oncology.
February 16, 2026
The BIOSECURE Act: Impact on Pharma Supply Chains & China Partnerships
How the landmark legislation signed December 2025 reshapes global biopharma manufacturing, CDMO relationships, and cross-border deal strategy.
February 16, 2026
Pharma Deal Tracker 2026: The Definitive M&A & Licensing Roundup
$240 billion in life sciences M&A. $250 billion across 516 licensing deals. The biggest dealmaking year in pharma history—and what it means for 2026.
February 16, 2026
Drug Development Stages: The Complete Guide from Discovery to Approval
A definitive walkthrough of every stage in the pharmaceutical development process—with timelines, costs, success rates, and strategic deal implications.
February 16, 2026
Cross-Border Licensing Term Sheet Guide: Structuring Pharma Deals That Work
A practical, clause-by-clause walkthrough of pharmaceutical licensing term sheets—with real-world benchmarks and China-specific negotiation strategies.
February 16, 2026
GLP-1 Licensing Landscape 2026: The Hottest Deal Space in Pharma
$50 billion in deal value. 8+ mega-deals. The race for next-gen oral, monthly, and combination obesity treatments.
February 16, 2026
rNPV Valuation Guide: The Gold Standard for Pharma Asset Valuation
A practical, step-by-step guide to risk-adjusted NPV—the methodology behind every major pharma licensing deal and acquisition.
February 16, 2026
Biotech IPO & Funding Landscape 2026: The Window Reopens
The biotech IPO market surged back to life in late 2025. Track the biggest offerings, venture trends, and what makes a successful biotech IPO.
February 16, 2026
Pharma Due Diligence Checklist: The Complete Guide for Licensing & M&A
A comprehensive, practical checklist covering scientific, IP, regulatory, commercial, financial, and manufacturing due diligence for pharma deals.
February 16, 2026
Japan Pharma Market Entry Guide: Navigating the World's 3rd Largest Market
How to enter Japan's ~$90B pharmaceutical market. PMDA pathways, NHI pricing, partnership models, and cultural considerations.
December 23, 2025
Biotech M&A 2026: Navigating the $200B Patent Cliff
A technical analysis of valuation multiples and integration savings in the consolidation wave.
December 22, 2025
Pharma Business Development: The 2026 Definitive Guide
Transforming the BD function from a transactional support role into a core scientific strategy engine.
December 21, 2025
China Biotech Licensing 2026: The Definitive Technical Guide
Navigating the world's second-largest market: From NMPA acceleration to the ADC licensing surge.
December 20, 2025
NewCo Formation: The 2026 Strategic Blueprint
A definitive guide to biopharma asset-centric company formation and venture strategy.
December 19, 2025
In-Licensing vs Out-Licensing: The Complete Guide
A strategic framework for cross-border asset acquisition, monetization, and partnership structuring.
